This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Induction of Mixed Hemopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2011 by King Faisal Specialist Hospital & Research Center.
Recruitment status was:  Recruiting
Sponsor:
Information provided by (Responsible Party):
King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:
NCT00531635
First received: September 17, 2007
Last updated: December 11, 2011
Last verified: December 2011
  Purpose
Induction of mixed hemopoietic chimerism in patients using Fludarabine, Low Dose TBI, PBSC Infusion and post transplant in immunosuppression w/CSA & Mycophenolate Mofetil

Condition Intervention Phase
Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil Drug: Mycophenolate Mofetil Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Induction of Mixed Hemopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil

Resource links provided by NLM:


Further study details as provided by King Faisal Specialist Hospital & Research Center:

Primary Outcome Measures:
  • Efficacy [ Time Frame: 2001-2012 ]

Estimated Enrollment: 350
Study Start Date: July 2002
Estimated Study Completion Date: June 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Mycophenolate Mofetil
    Induction of Mixed Hemopoietic Chimerism in Patients Using Mycophenolate Mofetil
  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients receiving Fludarabine, Low Dose TBI, PBSC Infusion and post transplant in immunosuppression w/CSA & Mycophenolate Mofetil.

Exclusion Criteria:

  • Uncontrolled major medical illnesses
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00531635

Contacts
Contact: Mahmoud AlJurf, MD 966-1-4647272 ext 24586 maljurf@kfshrc.edu.sa
Contact: Ed Colcol

Locations
Saudi Arabia
KFSH&RC Recruiting
Riyadh, Saudi Arabia, 11211
Contact: Mahmoud Aljurf, MD    966-1-4647272 ext 24586      
Contact: Ed Colcol    966-1-4647272 ext 38015    colcol@kfshrc.edu.sa   
Principal Investigator: Mahmoud Aljurf, MD         
Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Investigators
Principal Investigator: Mahmoud Aljurf, MD KFSH&RC
  More Information

Responsible Party: King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier: NCT00531635     History of Changes
Other Study ID Numbers: RAC#2001-051
Study First Received: September 17, 2007
Last Updated: December 11, 2011

Keywords provided by King Faisal Specialist Hospital & Research Center:
Mixed hemopoietic chimerism, Fludarabine, TBI, PBSC, immunosuppression, Mycophenolate Mofetil

Additional relevant MeSH terms:
Fludarabine
Fludarabine phosphate
Mycophenolic Acid
Mycophenolate mofetil
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Enzyme Inhibitors

ClinicalTrials.gov processed this record on July 24, 2017